It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rapid in situ detection of pathogens coupled with high resolution imaging in the distal human lung has the potential to provide new insights and diagnostic utility in patients in whom pneumonia is suspected. We have previously described an antimicrobial peptide (AMP) Ubiquicidin (fragment UBI29–41) labelled with an environmentally sensitive fluorophore that optically detected bacteria in vitro but not ex vivo. Here, we describe further chemical development of this compound and demonstrate that altering the secondary structure of the AMP to generate a tri-branched dendrimeric scaffold provides enhanced signal in vitro and ex vivo and consequently allows the rapid detection of pathogens in situ in an explanted human lung. This compound (NBD-UBIdend) demonstrates bacterial labelling specificity for a broad panel of pathogenic bacteria and Aspergillus fumigatus. NBD-UBIdend demonstrated high signal-to-noise fluorescence amplification upon target engagement, did not label host mammalian cells and was non-toxic and chemically robust within the inflamed biological environment. Intrapulmonary delivery of NBD-UBIdend, coupled with optical endomicroscopy demonstrated real-time, in situ detection of bacteria in explanted whole human Cystic Fibrosis lungs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Edinburgh, Edinburgh BioQuarter, EPSRC IRC PROTEUS Hub, Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 EaStCHEM, The University of Edinburgh School of Chemistry, Joseph Black Building, Edinburgh, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
3 University of Edinburgh, Clinical Research Imaging Centre, Queen’s Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 The University of Edinburgh, Easter Bush Veterinary Centre, The Roslin Institute and R(D)SVS, Roslin, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
5 Newcastle University, Freeman Hospital, High Heaton, Institute of Transplantation, Newcastle upon Tyne, United Kingdom (GRID:grid.4305.2)
6 University of Edinburgh, Edinburgh BioQuarter, EPSRC IRC PROTEUS Hub, Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); EaStCHEM, The University of Edinburgh School of Chemistry, Joseph Black Building, Edinburgh, United Kingdom (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)